Kosin University Gospel Hospital (Hospital Director Choi Jong-soon) and NKCL Bio Group (Chairman Shin Dong-hwa) are set to strengthen competitiveness in the field of advanced regenerative medicine through NK cell-based next-generation immune cell therapy research and clinical cooperation.

Kosin University Gospel Hospital (Hospital Director Choi Jong-soon, Vice President for Research Ok Cheol-ho, Head Representative of Advanced Regenerative Medicine Clinical Research Jang Hee-kyung, Professor Seo Kwang-il, Professor Shin Ho-sik, Professor Heo Jeong-hoon) is a medical institution that has continuously expanded the clinical applicability of advanced regenerative medicine and immune cell therapy, based on accumulated clinical experience and research infrastructure in the treatment of severe diseases including cancer.

In particular, with its strength in clinical data-driven research capabilities, the hospital has established a structure that connects research outcomes to actual treatment settings.

NKCL Bio Group is a company specializing in the development of personalized immune cell therapeutics utilizing NK cells, and has secured high-efficiency NK cell cultivation technology and production automation systems as its core competencies.

The company is focusing on building automated cultivation processes to overcome the production standardization and scalability limitations faced by the cell therapy industry, and is pursuing a clinical and commercialization-centered strategy that does not remain at the research stage.

This agreement is drawing attention as a substantive cooperation model that combines the hospital's clinical infrastructure with the bio company's cell therapy technology.

The two organizations plan to jointly pursue high-level projects including clinical research on NK cell combination therapy targeting intractable diseases including hepatocellular carcinoma, and the development of tumor microenvironment-overcoming NK cell therapeutics.

Industry observers view this cooperation as a potential turning point where domestic immune cell therapy research transitions from a technology development focus to a clinical value verification stage.

In particular, the structure of simultaneously pursuing clinical data acquisition and production technology advancement is expected to also impact the future commercialization competitiveness of immune cell therapeutics.

The cooperation between the two organizations is being recognized as a case of rapidly applying next-generation immune cell therapy technology to clinical settings and elevating the technological standards and execution capabilities of the domestic advanced regenerative medicine industry as a whole.